Pear Therapeutics is seeking marketing authorization from the Food and Drug Administration (FDA) for Somryst, a prescription digital therapeutic (PDT) intended for use in the treatment of adults with chronic insomnia and depression.
The benefit of CPAP was seen for depression but not anxiety symptoms in patients with obstructive sleep apnea.
De facto medical use of cannabis for symptom relief is common among adult-use dispensary customers in Colorado.
Stimulus control therapy and sleep restriction therapy are viable single-component treatments for chronic insomnia.
A recently published systematic review investigated the benefits and risks of melatonin supplementation for pediatric patients with sleep disturbances.
A new Boxed Warning will be required in the prescribing information for several insomnia medications following reports of serious injuries and deaths associated with complex sleep behaviors where patients engaged in activities while not fully awake.
Higher-than-recommended dosages were commonly prescribed to women who were new zolpidem users.
Predictors of neurodegeneration from idiopathic REM sleep behavior disorder (iRBD) have been identified.
Eisai and Imbrium Therapeutics announced that the Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for lemborexant, an investigational insomnia treatment.
This research supports the legitimacy of digital cognitive behavioral therapy as a treatment method for individuals with insomnia.
